哌柏西利联合芳香化酶抑制剂对HR+/HER2-绝经后晚期乳腺癌的疗效及安全性  

Efficacy and safety of palbociclib combined with aromatase inhibitors in advanced HR+/HER2-postmenopausal breast cancer

作　　者：崔宁[1] 蔡峰 曹武杰 王若明[1] Cui Ning;Cai Feng;Cao Wu-jie;Wang Ruo-ming(Department of Thyroid and Breast Surgery,Shangqiu First People’s Hospital,Shangqiu 476100,China)

机构地区：[1]商丘市第一人民医院甲状腺乳腺外科,商丘476100

出　　处：《中国药物应用与监测》2024年第6期792-796,共5页Chinese Journal of Drug Application and Monitoring

摘　　要：目的探究哌柏西利联合芳香化酶抑制剂对绝经后激素受体阳性/人表皮生长因子受体2阴性(HR+/HER2-)亚型晚期乳腺癌患者的疗效及安全性。方法选取2019年2月至2024年6月商丘市第一人民医院收治的110例绝经后HR+/HER2-乳腺癌晚期患者作为研究对象,将患者按照随机数字法分为对照组和试验组,每组55例。对照组患者给予芳香化酶抑制剂来曲唑治疗,试验组在对照组基础上加用哌柏西利,进行7个治疗周期。评估两组患者治疗前后的生活质量和疼痛程度,检测两组患者血清中肿瘤标志物糖类抗原153(CA153)和癌胚抗原(CEA)表达水平,评价两组药物疗效及不良反应发生情况。结果治疗后,试验组客观缓解率为94.55%(52/55),高于对照组的56.36%(31/55)(χ^(2)=47.632,P<0.05);治疗后,两组患者的生理功能、精神健康、活力、总体健康和生理职能评分较治疗前提高,且试验组患者的生理功能、精神健康、活力、总体健康和生理职能评分均高于对照组患者(t=13.048、15.386、15.523、8.152、7.045,均P<0.05);治疗后,两组患者的视觉模拟疼痛评分法(VAS)评分下降,且试验组患者的VAS评分[(6.02±0.95)分]低于对照组患者[(6.84±1.07)分](t=-4.250,P<0.05);治疗后,两组患者的血清CA153和CEA表达水平均较治疗前下降,且试验组患者血清CA153和CEA表达水平[分别为(13.20±1.58)U·mL^(-1)、(19.54±6.04)μg·L^(-1)]均低于对照组患者[分别为(18.54±1.61)U·mL^(-1)、(23.14±5.47)μg·L^(-1)](t=-17.556、-3.276,均P<0.05);两组患者均出现贫血、中性粒细胞数量减少、乏力和肝肾功能异常的不良反应,试验组不良反应发生率高于对照组[98.18%(54/55)vs 41.82%(23/55),χ^(2)=41.602,(P<0.001);试验组无进展生存期为(6.84±1.56)个月,对照组无进展生存期为(3.54±1.33)个月,组间差异有统计学意义(t=11.938,P<0.001)];两组患者在病情稳定情况比较差异无统计学意义[18.18%(10/55)vs 25.45%(14/55),Objective To investigate the safety and effectiveness of aromatase inhibitors in combination with palbociclib in postmenopausal women with advanced breast cancer of the hormone-receptor-positive/human epidermal growth factor receptor-2-negative(HR+/HER2-)subtype.Methods A total of 110 postmenopausal patients with advanced HR+/HER2-breast cancer admitted to Shangqiu First People’s Hospital from February 2019 to June 2024 were selected as the study objects.Using the random number table method,these patients were divided into the experimental group and control group,with 55 in each group.The patients in the control group were treated with aromatase inhibitor letrozole and those in the experimental group with Palbociclib in addition to letrozole for 7 treatment cycles.The patients’quality of life and pain level were assessed,the expression levels of serum tumor markers carbohydrate antinegen 153(CA153)and carcinoembryonic antigen(CEA)were detected before and after treatment,and the drug efficacy and adverse reactions of the two groups were evaluated.Results After treatment,the experimental group possessed a higher objective response rate(ORR)as compared with the control(94.55%(52/55)vs 56.36%(31/55),χ^(2)=47.632,P<0.05).Tthe scores of physiological function,mental health,vitality,general health and physiological function of the two groups were higher after than before treatment,and the scores of physiological function,mental health,vitality,general health and physiological function of the experimental group were higher than those of the control(t=13.048,15.386,15.523,8.152 and 7.045,all P<0.05).The Visual analogue scale(VAS)score of the two groups was significantly decreased after treatment,with a lower score in the experimental group as compared with the control((6.02±0.95)scores vs(6.84±1.07)scores)(t=-4.250,P<0.05).The expression levels of serum CA153 and CEA in both groups were significantly decreased after treatment,with lower expression levels in the experimental group than in the control((13.20±1.58)U�

关 键 词：哌柏西利 芳香化酶抑制剂 来曲唑 HR+/HER2-型乳腺癌 不良反应 药物治疗 

分 类 号：R737.9[医药卫生—肿瘤]